FactSet Survey Analysts Give CorMedix Buy Rating

Summary

According to a FactSet survey, analysts have given CorMedix an average rating of ‘Buy,’ with an average price target of $19.14.Trading View

Impact Analysis

This event is at the company level, specifically focusing on CorMedix Inc. The main subject is the analysts’ average rating and the price target increase for CorMedix. The event is significant as it demonstrates a positive shift in analysts’ expectations from $17.50 on June 24, 2025, to $19.14 by July 7, 2025.Trading View+ 2 This indicates growing confidence in the company, possibly due to recent developments or expected future performance. Although there was a downgrade by an analyst at D. Boral Capital from ‘Buy’ to ‘Hold,’Benzinga the general sentiment remains optimistic, potentially impacting the stock positively as investors gain confidence from the consensus ‘Buy’ rating. The price target increase suggests that the market may adjust its valuation of CorMedix upwards, offering potential investment opportunities for those looking to benefit from this upward momentum.